Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia

Neurologic Clinics

Volumn 26, Issue SUPPL.1, 2008, Pages 54-65

  Swope, David ^a   Barbano, Richard ^b  

^a LOMA LINDA UNIVERSITY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BACLOFEN; BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; LITHIUM; MEXILETINE; PHENOL; RILUZOLE; TETRABENAZINE; TIZANIDINE; TRIHEXYPHENIDYL;

AMNESIA; ARTICLE; BEHAVIOR CHANGE; BLURRED VISION; CERVICAL DYSTONIA; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPHONIA; DYSTONIA; ELECTROMYOGRAPHY; FATIGUE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPOTENSION; INJECTION PAIN; INJECTION SITE PAIN; LETHARGY; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINARY FREQUENCY; URINE RETENTION; XEROSTOMIA;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; HUMANS; PRACTICE GUIDELINES AS TOPIC; TORTICOLLIS;

EID: 46049087920     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(08)80005-9     Document Type: Article

References (39)

1. Chan J., Brin M., and Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 6 (1991) 119-126
2. Dauer W., Burke R., Greene P., and Fahn S. Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain 121 (1998) 547-560
3. Adler C., and Kumar R. Pharmacological and surgical options for the treatment of cervical dystonia. Neurology 55 Suppl 5 (2000) S9-S14
4. Burke R., Fahn S., and Marsden C. Torsion dystonia: a double blind, prospective trial of high-dosage trihexyphenidyl. Neurology 36 (1986) 160-164
5. Greene P., Shale H., and Fahn S. Analysis of open label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord 3 (1988) 46-60
6. Greene P., and Fahn S. Baclofen in the treatment of idiopathic dystonia in children. Mov Disord 7 (1992) 48-52
7. Narayan R., Loubser P., Jankovic J., et al. Intrathecal baclofen for intractable axial dystonia. Neurology 41 (1991) 1141-1142
8. Ford B., Greene P., Louis E., et al. Use of intrathecal baclofen in the treatment of patients with dystonia. Arch Neurol 53 (1996) 1241-1246
9. Greene P. Baclofen in the treatment of dystonia. Clin Neuropharmacol 15 (1992) 276-288
10. Benecke R., Moore P., Dressler D., and Naumann M. Cervical and axial dystonia. In: Moore P., and Naumann M. (Eds). Handbook of botulinum toxin treatment (2003), Blackwell Science, Ltd., Malden, Mass 158-194
11. Jankovic J. Treatment of dystonia. Lancet Neurol 5 (2006) 864-872
12. Ferreira J., Costa J., Coelho M., and Sampaio C. The management of cervical dystonia. Expert Opin Pharmacother 8 (2007) 129-140
13. Eltahawy H., Saint-Cyr J., Poon Y., et al. Pallidal deep brain stimulation in cervical dystonia: clinical outcome in four cases. Can J Neurol Sci 31 (2004) 328-332
14. Krauss J., Pohle T., Weber S., et al. Bilateral stimulation of globus pallidus internus for treatment of cervical dystonia. Lancet 354 (1999) 837-838
15. Parkin S., Aziz T., Gregory R., and Bain P. Bilateral internal globus pallidus stimulation for the treatment of spasmodic torticollis. Mov Disord 16 (2001) 489-493
16. Tassorelli C., Mancini F., Balloni L., et al. Botulinum toxin and neuromotor rehabilitation: an integrated approach to idiopathic cervical dystonia. Mov Disord 21 (2006) 2240-2403
17. Comella C., Jankovic J., and Brin M. Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology 55 Suppl 5 (2000) S15-S21
18. Comella C., Jankovic J., Shannon K., et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 65 (2005) 1423-1429
19. Costa J., Espírito-Santo C., Borges A., et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 1 (2005) CD003633
20. Papapetropoulos S., and Singer C. Botulinum toxin in movement disorders. Semin Neurol 27 (2007) 183-194
21. Comella C., and Thompson P. Treatment of cervical dystonia with botulinum toxins. Eur J Neurol 13 Suppl 1 (2006) 16-20
22. Yablon S., Brashear A., Gordon M., et al. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther 29 (2007) 683-690
23. Naumann M, Daggett S, Kumar C, et al. Toxin neutralizing antibody formation with botulinum toxin type A treatment in the treatment of primary axillary hyperhidrosis. Poster presented at: ACADEMY '05 meeting of the American Academy of Dermatology; July 21-24, 2005; Chicago, Ill. Poster #P39.
24. Atassi M. Basic immunological aspects of botulinum toxin therapy. Mov Disord 19 Suppl 8 (2004) S68-S84
25. Jankovic J., Vuong K., and Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60 (2003) 1186-1188
26. Jankovic J., Hunter C., Dolimbek B., et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 67 (2006) 2233-2235
27. Kessler K., and Benecke R. The EBD test-a clinical test for the detection of antibodies to botulinum toxin type A. Mov Disord 12 (1997) 95-99
28. Brin M., Lew M., Adler C., et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology 53 (1999) 1431-1438
29. Dashtipour K., and Lew M. Cervical dystonia. In: Stacy M. (Ed). Handbook of dystonia (2007), Informa Healthcare, USA, Inc., New York, NY 137-153
30. Barbano R. Anatomic principles for botulinum toxin injection. In: Stacy M. (Ed). Handbook of dystonia (2007), Informa Healthcare, USA, Inc., New York, NY 317-341
31. Barbano R. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is useful. Muscle Nerve 24 (2001) 1567-1568
32. Ostergaard L., Fuglsang-Frederiksen A., Werdelin L., et al. Quantitative EMG in botulinum toxin treatment of cervical dystonia. A double-blind, placebo-controlled study. Electroencephalogr Clin Neurophysiol 93 (1994) 434-439
33. Barbano RL, Comella C, Fan W, Leurgans S, for the Dystonia Study Group. Utility of adjunctive electromyography in botulinum toxin injection for cervical dystonia. Presented at 9th International Conference of Parkinson's Disease and Movement Disorders; March 5-8, 2005; New Orleans, La.
34. Jankovic J. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve 24 (2001) 1568-1570
35. Comella C., Buchman A., Tanner C., et al. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 42 (1992) 878-882
36. Cordivari C., Misra V., Vincent A., et al. Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test. Mov Disord 21 (2006) 1737-1741
37. Poewe W., Deuschl G., Nebe A., et al., for the German Dystonia Study Group. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry 64 (1998) 13-17
38. Thobois S., Broussolle E., Toureille L., and Vial C. Severe dysphagia after botulinum toxin injection for cervical dystonia in multiple system atrophy. Mov Disord 16 (2001) 764-765
39. Costa J., Borges A., Espírito-Santo C., et al. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev (2005) 1CD004314